TY - JOUR
T1 - StrataXRT for the prevention and treatment of radiation dermatitis
T2 - a critical review
AU - Gojsevic, Milena
AU - Akkila, Shereen
AU - Kennedy, Samantha K.F.
AU - Herst, Patries
AU - Ogita, Mami
AU - Ye, Jason C.
AU - Shariati, Saba
AU - Rajeswaran, Thenugaa
AU - Behroozian, Tara
AU - Lee, Shing Fung
AU - Chan, Raymond J.
AU - Chow, Edward
PY - 2023/12
Y1 - 2023/12
N2 - Purpose: The primary objective is to systematically review primary studies, such as randomized control trials (RCTs), feasibility, exploratory, and case studies; and the secondary objective is to evaluate all secondary articles, such as reviews, guidelines, and editorials, relevant to the use of StrataXRT for the prevention and/or management of radiation dermatitis (RD) in cancer patients. Methods: A literature search was conducted up to February 26, 2023, for articles investigating the use of StrataXRT for the prevention and treatment of RD, in the following databases: Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar. The keywords “StrataXRT”, “dermatitis”, “radiotherapy”, and “radiation” were used to identify relevant articles. Results: Twenty-seven articles from 2018 to 2022 were identified to fulfill the inclusion criteria of this review, of which nine are primary studies and 18 are secondary papers. Significant heterogeneity was observed in the current literature studying the effects of StrataXRT, making it difficult to make cross-trial comparisons. There is a suggestion of the efficacy of StrataXRT in the prevention and treatment of RD. Conclusion: The findings of this review recommend further adequately powered RCTs with robust methodology including patient and clinician assessments to determine the efficacy of StrataXRT in preventing and treating RD. This is essential to improve the quality of life of patients and identify which groups of patients would benefit most from StrataXRT.
AB - Purpose: The primary objective is to systematically review primary studies, such as randomized control trials (RCTs), feasibility, exploratory, and case studies; and the secondary objective is to evaluate all secondary articles, such as reviews, guidelines, and editorials, relevant to the use of StrataXRT for the prevention and/or management of radiation dermatitis (RD) in cancer patients. Methods: A literature search was conducted up to February 26, 2023, for articles investigating the use of StrataXRT for the prevention and treatment of RD, in the following databases: Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar. The keywords “StrataXRT”, “dermatitis”, “radiotherapy”, and “radiation” were used to identify relevant articles. Results: Twenty-seven articles from 2018 to 2022 were identified to fulfill the inclusion criteria of this review, of which nine are primary studies and 18 are secondary papers. Significant heterogeneity was observed in the current literature studying the effects of StrataXRT, making it difficult to make cross-trial comparisons. There is a suggestion of the efficacy of StrataXRT in the prevention and treatment of RD. Conclusion: The findings of this review recommend further adequately powered RCTs with robust methodology including patient and clinician assessments to determine the efficacy of StrataXRT in preventing and treating RD. This is essential to improve the quality of life of patients and identify which groups of patients would benefit most from StrataXRT.
KW - Patient-reported outcome
KW - Radiation dermatitis
KW - Review
KW - Skin toxicity
KW - StrataXRT
UR - http://www.scopus.com/inward/record.url?scp=85177475525&partnerID=8YFLogxK
U2 - 10.1007/s00520-023-08190-8
DO - 10.1007/s00520-023-08190-8
M3 - Review article
AN - SCOPUS:85177475525
SN - 0941-4355
VL - 31
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 12
M1 - 713
ER -
